# AnaCardio

> Swedish cardiovascular biotech that raised €62.5 million in Series B financing for a chronic advanced heart-failure program.

## Why it is interesting

Large European life-sciences round supporting a program moving toward registrational development.

## Profile

- **Latest funding:** Series B — €62.5M (~$70.9M) (September 29, 2026)
- **Latest known valuation:** Not publicly disclosed
- **Total disclosed equity funding:** Not publicly disclosed
- **Stage:** series-b
- **Status:** private
- **Industries:** N/A
- **Coverage:** full
- **Last updated:** 2026-09-30

## Key facts

- Sep 29, 2026: €62.5M Series B reported
- Secondary-source verification; retain draft review

## Funding history

- Series B · €62.5M (~$70.9M) · September 29, 2026
  Source: https://biobriefs.com/fda-backs-anacardios-heart-failure

**By:** [Venture Capital Tracker](https://venturecapitaltracker.com/editorial-policy)
**Last updated:** September 30, 2026

**Editorial note:** AI tools assisted with research, structure, or drafting. Venture Capital Tracker retains human editorial responsibility for factual accuracy, relevance, and source quality before publication.

---
Source: https://venturecapitaltracker.com/startup/anacardio